◀ Back to SRC
GNRH1 — SRC
Text-mined interactions from Literome
Harris et al., Endocrinology 2002
:
Interestingly, the constitutively active form of c-Src stimulated the basal and the GnRH-A response, whereas the dominant negative form of
c-Src , or the c-Src inhibitor PP1
diminished basal and the
GnRH-A response
Shah et al., J Biol Chem 2003
(MAP Kinase Signaling System) :
GnRH stimulation caused translocation of PKC alpha and -epsilon to the cell membrane and
enhanced the association of
Src with PKC alpha and PKC epsilon, Pyk2, and the EGF receptor
Harris et al., Endocrinology 2003
:
Thus, ERK and
c-Src but not JNK are
involved in basal and
GnRH-A-stimulated-alphaCAT , whereas c-Src contribution is independent of ERK activation
Roelle et al., J Biol Chem 2003
(MAP Kinase Signaling System) :
We found that
GnRH induced
Src , Ras, and ERK activation were also gelatinase dependent
Davidson et al., J Biol Chem 2004
:
Using matrix assisted laser desorption ionization time-of-flight mass spectrometry we identified a
GnRH induced association between
c-Src and the lipid kinase, diacylglycerol kinase-zeta (DGK-zeta)
Bonfil et al., Endocrinology 2004
:
Extracellular signal regulated kinase, Jun N-terminal kinase, p38, and
c-Src are
involved in
gonadotropin releasing hormone stimulated activity of the glycoprotein hormone follicle stimulating hormone beta-subunit promoter ... Thus, PKC, ERK, JNK, p38, and
c-Src , but not Ca ( 2+ ), are
involved in
GnRH induction of the ovine FSHbeta gene
Maudsley et al., Neuroendocrinology 2006
:
GnRH induced
c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor
Maudsley et al., Mol Endocrinol 2007
:
We show that
GnRH activates
c-Src and multiple members of the MAPK family, c-Jun NH2-terminal kinase 1/2, p38MAPK, and ERK1/2
Levi et al., Mol Endocrinol 1998
:
GnRH as well as tumor promoting agent ( TPA ) also
increased c-Src activity, which peaked at 2 min after GnRH stimulation and was sensitive both to PKC and to tyrosine kinase inhibitors